

Table 3. Incidence rates of IRAEs endocrine sequelae. (data from Barroso-Sousa et al⁴⁷)

	Hypophysitis incidence rate (95% CI)	Hypothyroidism incidence rate (95% CI)	Hyperthyroidism incidence rate (95% CI)	Primary adrenal insufficiency N of pts with PAI/ total n of pts (%)*	N of pts with DM1/ total n of pts (%)
Anti-CTLA4	0.0 (0.0-6.7) - 6.5 (1.4-17.9)	0.0 (0.0-45.9) - 15.2 (6.3-28.9)	0.0 (0.0-45.9) - 2.3 (0.9-5.0)		
Anti-PDL1	0.0 (0.0-5.9) - 3.0 (0.1-15.8)	0.0 (0.0-1.2) - 5.6 (2.5-10.8)	0.0 (0.0-1.2) - 0.7 (0.2-1.8)	43/5831 (0.7%)**	
Anti-PD1		0.0 (0.0-30.8) - 40.0 (19.1-63.9)	0.0 (0.0-9.0) - 7.7 (1.6-20.9)		13/5831 (0.2%***)
Combination	3.8 (0.5-13.0) - 11.7 (6.0-20.0)	3.8 (0.5-13.0) - 16.0 (9.2-25.0)	3.8 (0.5-13.0) - 9.9 (6.8-13.8)	11/262 (4.2%)	

*number of patients with primary adrenal insufficiency as adverse event following immune check point inhibitors therapy/total number of patients who received ICIs therapy.

** Refers to pts taking Anti-CTLA4/Anti-PDL1/Anti-PD1; *** Refers to pts taking Anti-CTLA4/Anti-PDL1/Anti-PD1 or combination of them.

PAI: primary adrenal insufficiency; DM1: diabetes mellitus type 1.